Cover Image
市場調查報告書

市場進入的影響 (EU5個國家):第二型糖尿病 (口服藥)

Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018

出版商 FirstWord 商品編碼 593153
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
市場進入的影響 (EU5個國家):第二型糖尿病 (口服藥) Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018
出版日期: 2018年04月01日 內容資訊: 英文
簡介

本報告依據歐洲主要5個國家從事第二型糖尿病的治療的150名醫療專家的問卷調查結果,提供糖尿病的治療藥 (口服藥)的採購、使用相關問題點相關分析,基本的市場結構和主要企業、品牌的市場佔有率,各公司現在面臨的主要障礙 (市場進入等),障礙的主要原因 (各種法規等),應採取對策的資訊彙整,為您概述為以下內容。

第二型糖尿病 (T2DM)的治療用主要的口服藥

  • Forxiga (dapagliflozin; AstraZeneca)
  • Glyxambi (empagliflozin/linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Invokana (canagliflozin; Janssen Cilag)
  • Januvia (sitagliptin; Merck Sharp & Dohme)
  • Jardiance (empagliflozin; Eli Lilly/Boehringer Ingelheim)
  • Onglyza (saxagliptin; AstraZeneca)
  • Qtern (saxagliptin/dapagliflozin; AstraZeneca)
  • Trajenta (linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Vipidia (alogliptin;Takeda)

目錄

  • 「市場障礙」是什麼?
  • 本報告
  • 關於此次分析
  • 調查對象品牌
  • 摘要整理
目錄

Market barriers affect a fifth of oral diabetes treatment prescriptions in Europe. Is your brand losing out?

Market barriers affect over a fifth of all oral type 2 diabetes mellitus (T2DM) prescriptions in Europe, and certain brands are losing out on market share big time. Is it yours? Find out what's driving share gains, and what your brand can do to level the playing field in Market Access Impact: Type 2 Diabetes Mellitus (Orals) (EU5) [2018].

Based on a survey of 150 European diabetologists from the leading EU5 markets (France, Germany, Italy, Spain, and the UK), the report covers 9 major oral therapies from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Janssen Cilag, Merck Sharp & Dohme, and Takeda. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Barriers affect just over a fifth of all prescriptions. Small, perhaps, but brands are still losing out on market share opportunities because of them. is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • One brand sees a robust share increase. Is this lead too big for the chasing pack to overcome? Is your brand leading, or are you in the chasing pack?
  • Two brands see a significant loss. Could market share losses be due to low prescribing rates, or is some other market dynamic at play? And perhaps most importantly, can this be prevented?
  • Eliminating barriers would have limited impact. Due to the overall barrier impact being 20 percent, eliminating barriers would have limited impact on market share performance.
  • Perception is a huge problem. Across all but one of the brands, a certain proportion of physicians have never heard of the treatment. Could improved physician education be the key to better market shares?

Insight into 9 Oral Type 2 Diabetes Mellitus Treatments

  • Forxiga (dapagliflozin; AstraZeneca)
  • Glyxambi (empagliflozin/linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Invokana (canagliflozin; Janssen Cilag)
  • Januvia (sitagliptin; Merck Sharp & Dohme)
  • Jardiance (empagliflozin; Eli Lilly/Boehringer Ingelheim)
  • Onglyza (saxagliptin; AstraZeneca)
  • Qtern (saxagliptin/dapagliflozin; AstraZeneca)
  • Trajenta (linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Vipidia (alogliptin; Takeda)

Exploring Market Access Barriers

Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) explores key issues affecting type 2 diabetes mellitus drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 diabetologists and primary care physicians-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world. All respondents have:

All respondents:

  • Have been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with type 2 diabetes mellitus in total in the last month

We conducted the survey between April 5-10, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Table of Contents

1. What are market barriers?

2. About this report

3. About the survey

4. Brands included in the survey

5. Executive summary

Back to Top